Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Date:10/27/2011

elopment of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
2. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
4. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
5. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
6. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
8. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... , SILVER SPRING, Md., Nov. 13 The U.S. ... acid), the first non-hormonal product cleared to treat heavy ... that helps blood to clot. , (Logo: ... is reported each year by about 3 million U.S. ...
... FRANCISCO, Nov. 13 Quantros, a leading software ... that it has partnered with Det Norske Veritas ... by the Centers for Medicare and Medicaid Services ... now integrate that company,s accreditation standards into the ...
Cached Medicine Technology:FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2Quantros Announces Partnership With Hospital Accreditation Agency DNV 2
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... identified an important enzyme pathway that helps prevent new ... a condition that has been directly linked to cancer ... biochemistry, found that near the end of cell division, ... any breaks in DNA are fully repaired before the ... cells. This process helps safeguard against some of the ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of medical miracles and the very latest in scientific ... (FBR) announced today it will distribute its free daily ... experiencing tremendous success in select markets. The Animal ... medical miracles and latest scientific breakthroughs. The host ...
... the University of Exeter reveals for the first ... physical exercise, may help reduce cigarette cravings. Published ... shows how exercise changes the way the brain ... for nicotine. For the first time, researchers used ...
... Erdman, A Cogdell Spencer,Company is pleased to ... earned the U.S. Environmental Protection Agency,s (EPA,s),prestigious ENERGY ... environmental protection. America,s commercial buildings and industrial,plants that ... facilities for energy,efficiency may qualify for the ENERGY ...
... Help Set Unprecedented NumbersVIRGINIA BEACH, Va., Feb. 10 ... able to save the lives of 406 people ... 2008.LifeNet Health saw a 13% increase from 2007 ... to hospitals and physicians. LifeNet Health provided ...
... Samples taken from the 39 hunter-killed elk during ... negative for chronic wasting disease (CWD), according to ... veterinarian. Samples also tested negative for brucellosis ... is awaiting the results of CWD testing for ...
... China Sky One,Medical, Inc. (,China Sky One Medical, ... a,leading fully integrated pharmaceutical company producing over-the-counter,drugs in ... its,revenue and net income guidance for the full-year ... to continued strong organic growth and contribution from ...
Cached Medicine News:Health News:Foundation for Biomedical Research Announces National Distribution of Daily Radio Broadcast 2Health News:First brain study reveals benefits of exercise on quitting smoking 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 3Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 4Health News:LifeNet Health Announces a Record Year of Saving Lives and Restoring Health 2Health News:LifeNet Health Announces a Record Year of Saving Lives and Restoring Health 3Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 2Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 3Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 4Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 5Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 2Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 3
... part of the AXIOM family, which ... the clinical angiography, card- angiography, and ... functional and business pages you can ... delivers unrivalled value to users and ...
Spring Type with lock. Titanium....
.60 x 22mm, angled 60, .33mm end port [Simcoe]...
... The STARFlex is a fourth generation ... CardioSEAL by the addition of a unique ... coil micro-spring. The micro-spring is attached to ... and provides a self-adjusting positioning mechanism which ...
Medicine Products: